新发2型糖尿病患者动脉粥样硬化与血浆不对称性二甲基精氨酸关系研究被引量：2

Association between artery atherosclerosis and plasma ADMA in type 2 diabetes patients

下载PDF

导出

摘要目的：探讨新发的2型糖尿病（T2DM）患者动脉粥样硬化（AS）与血浆不对称性二甲基精氨酸（ADMA）浓度的关系。方法：收集2008年6月～2009年12月曲靖市第三人民医院内科住院新诊断并且病程在5年之内的60例T2DM患者以及与其性别、年龄匹配的健康查体40例作为对照组，采用彩色多普勒超声检测颈动脉内膜-中层厚度（IMT）及粥样硬化斑块情况，酶联免疫吸附（ELISA）法检测血浆ADMA浓度，生化分析仪检测空腹血糖（FBS）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL—C）。结果：T2DM患者IMT值为（1．2±0．6）mm，显著厚于对照组的（0．4±0．1）mm（P〈0．01）；T2DM组患者动脉粥样斑块检出率为59．2％，显著高于对照组的12．4％（P〈0．01）；T2DM组患者血浆ADMA浓度（16．9±7．6）μmol／L，高于对照组的（1．5±0．4）μmol／L，差异有统计学意义（P〈0．01）；相关分析表明颈动脉IMT值与血浆ADMA成正相关（r=0．84，P〈0．05）。结论：T2DM患者血浆ADMA水平明显增高，ADMA在AS的发生、发展中可能起了重要作用。 Objective： To investigate the association between artery atherosclerosis and plasma asymmetric dimethylarginine（ADMA） concentration in type 2 diabetes patients who were new diagnosed. Methods： 60 cases of 2 diabetes patients and 40 cases of age-matched healthy controls from the third people＇s hospital of Qujing City from June 2008 to December 2009,were enrolled in this study. Color Doppler ultrasonography was used to determine intimamedial thickness （IMT） of carotid artery and atherosclerotic plaques, plasma ADMA levels were determined by ELISA, and fasting blood sugar, triaglyceride, cholesterol and low density lipoprotein were measured by automatic biochemistry analysis apparatus. Results： The mean IMT value （1.2±0.6） mm in type 2 diabetes patients were higher than those of controls （0.4±0.1） mm （P〈0.01）; and the ar- terial carotis atheromatous plaque detection rate （59.2%） in type 2 diabetes patients were also higher than those of controls （12.4%）（P〈0.01）; the plasma ADMA levels （16.9±7.6） μmol/L in type 2 diabetes patients were significantly higher than the controls（1.5±0.4）μmol/L （P〈0.01）; linear correlation analysis demonstrated carotid artery IMT correlated with blood plasma ADMA level （r=0.84, P〈0.05）. Conclusion： In type 2 diabetes patients, atherosclersis is related to blood plasma ADMA levels, and blood plasma ADMA may play an important role in development and progression of artery atherosclerosis.

作者朱志雾晏桂萍甘梅松杨春霓

机构地区云南省曲靖市第三人民医院内科云南省曲靖市妇幼医院产科云南省宣威市第一人民医院内科

出处《中国医药导报》 CAS 2011年第31期47-49,共3页 China Medical Herald

关键词 2型糖尿病不对称性二甲基精氨酸动脉粥样硬化 Type 2 diabetes Asymmetric dimethylarginine Artery atherosclerosis

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献13

1Szuba A, Podgorski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor evidence from epidemiological and prospective clinical trials[J]. Pharmacol Rep,2006,58(Suppl):16-20.
2Hollander M, Hak AE, Koudstaalp J, et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study [J]. Stroke,2003,34( 10):2367-2372.
3程洁,吕宝经,郑宏超,徐伟平,张亚臣.颈动脉粥样硬化与冠状动脉狭窄程度的关系[J].中国动脉硬化杂志,2004,12(1):65-68. 被引量：81
4Kitamura A, Iso H, Imano H, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men [J].Stroke,2004,35(12): 2788-2794.
5Boger RH, Bode-Boger SM. Asymmetrical dimethylarginine, derangments of the endothelial nitric oxide synthase pathway and cardiovascular disease[J]. Sere Thromb Hemost,2000,26(5):539-545.
6Vallance P, Leiper J. Cardiovascular biology of the asymmetrical dimethylarginine: dimethylarginine dimethylaminohydrolase pathway[J]. Arterioscler Thmmb Vasc Biol, 2004,24(6): 1023-1030.
7廖清池,李向平.非对称性二甲基精氨酸与内皮功能障碍[J].心血管病学进展,2007,28(6):975-978. 被引量：2
8张翼飞,詹维伟,洪洁,顾卫琼,杨义生,桂明辉,唐金凤,王卫庆,刘建民,赵咏桔,宁光.糖耐量受损人群颈动脉内中膜厚度与各代谢指标的关系[J].中华糖尿病杂志（1006-6187）,2005,13(1):23-26. 被引量：35
9姜涛,宋秀霞,张敏.2型糖尿病颈动脉内膜中膜厚度与胰岛素抵抗的关系[J].中华糖尿病杂志（1006-6187）,2005,13(4):260-261. 被引量：12
10Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes[J]. J Clin Endocrinol Metab,2001,86(7):3452-3456.

二级参考文献62

1Caglar K, Yilmaz MI, Sonmez A,et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney diseas e [ J]. Kidney Int,2006,70:781 - 787.
2Hollander M, Hak AE, Koudstaalp J, et al. Comparison between measures of atheroselerosis and risk of stroke:the Rotterdam Study [ J ]. Stroke ,2003,34:2367 - 2372.
3United States Renal Data System. 1998 Annual report:The National Institute of Diabetes and Digestive and Kidney Diseases [ J ]. Am J Kidney Dis, 1998,32 : S81 - S88.
4Tanmw L, Hovind P, Teerlink T et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes[ J]. Diabetes Care,2004, 27:765 - 769.
5Kielstein JT, Bode-Boger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension [ J ]. Arterioscler Thromb Vasc Biol,2005 ,15 :852 - 855.
6Zoccali C, Bode-Boger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease : a prospective study [ J]. Lancet ,2001,358 (9299) :2113 -2117.
7Jacobi J,Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review[ J]. Am J Nephrol,2008 ,28 :224 - 237.
8De Gennaro Colonna V, Bianchi M, et al. Asymmetric dimethylarginine(ADMA) :an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule [ J ]. Med Sci Monit, 2009,15 : RA91 - RA101.
9Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine,c-reactive protein, and carotid intima-media thickness in endstage renal disease[ J ]. J Am Soc Nephrol,2002 ,13 :490 -496.
10Wagenknecht LE, D' Agostino RB, Haffner SM, et al. Impaired glucose tolerance type 2 diabetes and carotid wall thickness- the insulin resistance atherosclerosis study. Diabetes Care, 1998, 21:1812-1818.